Zoetis Inc Stock Price, News & Analysis

Phibro Animal Health (PAHC) has completed the acquisition of Zoetis' medicated feed additive portfolio and certain water-soluble products. The acquisition includes 37+ product lines across approximately 80 countries, six manufacturing sites in the U.S., Italy and China, and a team of over 300 employees. The portfolio is expected to enhance Phibro's profitability, EBITDA margin, and Adjusted Earnings Per Share. The deal expands Phibro's species and product portfolios across cattle, swine, and poultry sectors, complementing their existing lineup of vaccines, nutritional specialties, and mineral nutrition.

Zoetis Inc. (NYSE:ZTS), a leading animal health company, has announced its fourth quarter 2024 dividend. The Board of Directors has declared a dividend of $0.432 per share. This dividend will be paid on Tuesday, December 3, 2024, to shareholders of record as of the close of business on Thursday, October 31, 2024. This announcement demonstrates Zoetis' commitment to returning value to its shareholders through regular dividend payments.

Zoetis and Danone have announced a strategic partnership to drive sustainable practices in dairy farming through genetic innovation. The collaboration aims to leverage Zoetis' genetic technologies globally, focusing on animal well-being, reducing environmental impact, and promoting long-term resilience in dairy farming.

Zoetis, as Danone's preferred provider for genetic testing on dairy farms, will utilize its Dairy Wellness Profit Index® (DWP$®) from CLARIFIDE® Plus. This multi-trait animal ranking selection index helps estimate the potential lifetime profit of Holstein and Jersey cattle, incorporating critical wellness traits, production, fertility, and other factors.

The partnership aims to improve environmental, resource, and operational sustainability outcomes in dairy farming. Recent studies have shown potential benefits for sustainability, methane reduction, farm profitability, and animal welfare through genetic improvements.

Zoetis Inc. (NYSE:ZTS), a leading animal health company, has announced it will host a webcast and conference call on Monday, November 4, 2024, at 8:30 a.m. (ET) to discuss its third quarter 2024 financial results. The event will feature CEO Kristin Peck and CFO Wetteny Joseph, who will review the company's performance and address questions from financial analysts.

Investors and the public can access the live webcast through the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration information is now available, and a replay of the webcast will be accessible on the same day.

Zoetis Inc. (NYSE:ZTS), a leading animal health company, is set to participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. The company will be represented by CEO Kristin Peck and CFO Wetteny Joseph, who will engage in a Q&A session with analysts at 1:05 p.m. ET.

Investors and interested parties can access a live audio webcast of the session through the Zoetis investor relations website. A replay of the event will also be made available on the same platform after the conference concludes. This participation underscores Zoetis' commitment to engaging with the financial community and providing insights into its business strategies and market position.

Zoetis Inc. (NYSE:ZTS) reported strong Q2 2024 results, with revenue of $2.4 billion, up 8% (11% operational growth). Net income was $624 million ($1.37 per diluted share), down 7% and 6% respectively. Adjusted net income reached $711 million ($1.56 per diluted share), up 9% and 11% on a reported basis, and 18% and 20% operationally.

The company saw impressive growth in both U.S. (12%) and International (10% operational) segments, with strong performance in companion animal and livestock portfolios. Key drivers included osteoarthritis pain products, Simparica Trio, and dermatology offerings.

Zoetis raised its full-year 2024 guidance, projecting revenue between $9.100-$9.250 billion (9-11% operational growth) and adjusted diluted EPS of $5.78-$5.88.

Zoetis Inc. (NYSE:ZTS) has announced a $6 billion multi-year share repurchase program, approved by its Board of Directors. This program, the company's largest to date, is expected to run for up to four years and can be cancelled at any time. The announcement reflects Zoetis' strong performance, positive long-term outlook, and commitment to returning capital to shareholders.

Wetteny Joseph, Executive VP and CFO, emphasized that Zoetis remains an attractive investment opportunity due to its consistent performance and business outlook. The company's previous $3.5 billion share repurchase program, approved in December 2021, is anticipated to be completed in 2024.

Zoetis Inc. (NYSE:ZTS) has announced a time change for its second quarter 2024 financial results webcast and conference call. The event will now take place at 8:00 a.m. (ET) on Tuesday, August 6, 2024. This adjustment aims to minimize conflicts with other industry earnings announcements. Investors and the public can access the live webcast through the Zoetis website at http://investor.zoetis.com/events-presentations. The webcasting information remains unchanged, and a replay of the webcast will be available on the same day.

Zoetis (NYSE: ZTS) will host a webcast and conference call to discuss its second quarter 2024 financial results on Tuesday, August 6, 2024, at 8:30 a.m. (ET). CEO Kristin Peck and CFO Wetteny Joseph will review the results and answer questions from financial analysts. The webcast will be accessible through the Zoetis investor website, with pre-registration information available now. A replay of the webcast will be available starting the same day.